Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trulieve CannabisSTU:T0A +0.77%63 Days Payable is 41.21 as of Mar. 2026, which is 123% above its 10-year median of 18.52. GuruFocus rates STU:T0A with a GF Score™ of 63/100 and a GF Value™ of €5.24 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 927 Drug Manufacturers companies, Trulieve Cannabis ranks worse than 71.2% on this metric.
The historical rank and industry rank for Trulieve Cannabis's Days Payable or its related term are showing as below:
STU:T0A'
s Days Payable Range Over the Past 10 Years
Min: 10.57 Med: 18.52 Max: 86.24
Current: 55.23
During the past 10 years, Trulieve Cannabis's highest Days Payable was 86.24. The lowest was 10.57. And the median was 18.52.
STU:T0A's Days Payable is ranked worse than 71.2% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs STU:T0A: 55.23
Trulieve Cannabis's Days Payable
declined
from Mar. 2025 (44.63) to Mar. 2026 (41.21).
It may suggest that Trulieve Cannabisaccelerated paying its suppliers.
Trulieve Cannabis Days Payable Related Terms
Trulieve Cannabis Days Payable Historical Data
* Premium members only.
The historical data trend for Trulieve Cannabis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:T0A vs HROW, ANIP, AMLX: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Trulieve Cannabis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trulieve Cannabis Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Trulieve Cannabis's Days Payable distribution charts can be found below:
* The bar in red indicates where Trulieve Cannabis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Trulieve Cannabis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trulieve Cannabis (STU:T0A) has a Days Payable of 41.21 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Trulieve Cannabis and its competitors. This is 123% above median its historical median of 18.52. Over the past decade, Trulieve Cannabis' Days Payable has ranged from 10.57 to 86.24. According to the industry distribution chart, Trulieve Cannabis ranks #660 out of 927 companies in the Drug Manufacturers industry, placing it in the top 71.2%.
Is Trulieve Cannabis' Days Payable too high?
Trulieve Cannabis' current Days Payable of 41.21 is 123% above median its 10-year median of 18.52. Over the past 10 years, this metric has ranged from a low of 10.57 to a high of 86.24. The Drug Manufacturers industry median Days Payable is 90.38. Trulieve Cannabis' value of 41.21 is 54.4% below this industry median. Based on the distribution chart, Trulieve Cannabis ranks #660 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Trulieve Cannabis has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Trulieve Cannabis' Days Payable compare to HROW and ANIP?
According to the Drug Manufacturers industry distribution chart, Trulieve Cannabis ranks #660 out of 927 companies for Days Payable. This places Trulieve Cannabis in the lower half of its industry. The industry median Days Payable is 90.38. Trulieve Cannabis' value of 41.21 is 54.4% below this benchmark. Historically, Trulieve Cannabis' own Days Payable has ranged from 10.57 to 86.24 over the past decade. While the company's 10-year median is 18.52 vs. the industry median of 90.38, Trulieve Cannabis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trulieve Cannabis's current Days Payable of 41.21 is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Trulieve Cannabis and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trulieve Cannabis's current Days Payable is 41.21, which is 123% above median its own 10-year median of 18.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trulieve Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Trulieve Cannabis (STU:T0A) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.24, compared to a current price of €7.88 — trading 50.4% above its estimated fair value. The current Days Payable is 41.21, which is 123% above median its 10-year median of 18.52 and 54.4% below the Drug Manufacturers industry median of 90.38. Trulieve Cannabis' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Trulieve Cannabis (STU:T0A), the current Days Payable is 41.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trulieve Cannabis (STU:T0A) Overvalued in 2026?
Based on GuruFocus' analysis, Trulieve Cannabis stock appears to be overvalued.
The current stock price of €7.88 is trading 50.4% above its estimated GF Value™ of €5.24.
GuruFocus considers Trulieve Cannabis to be Significantly Overvalued.
Key valuation signals for STU:T0A:
Days Payable: 41.21 (123% above median its 10-year median of 18.52)
GF Value™: €5.24 vs. price of €7.88 (50.4% above fair value)
Industry Position: 54.4% below the Drug Manufacturers median (#660 of 927)
No single metric tells the full story. See the STU:T0A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trulieve Cannabis Corp is a vertically integrated cannabis company that grows, produces, and sells cannabis products. It has licenses to operate in Arizona, Colorado, Connecticut, Florida, Georgia, Maryland, Ohio, Pennsylvania, and West Virginia, where it sells medical cannabis products. In addition, the company sells cannabis products for adult use in Arizona, Colorado, Connecticut, Maryland, and Ohio. The firm's operations are substantially located in Florida and, to a lesser extent, in Arizona and Pennsylvania.
63GF Score
Get the complete analysis for STU:T0A
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:T0A has been successfully added to your 
